

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

EMILIO ALBA, ANA LLUCH, NURIA RIBELLES, ANTONIO ANTON-TORRES, PEDRO SANCHEZ-ROVIRA, JOAN ALBANELL, LOURDES CALVO, JOSE ANTONIO LOPEZ GARCÍA-ASENJO, JOSE PALACIOS, JOSE IGNACIO CHACON, AMPARO RUIZ, JUAN DE LA HABA-RODRIGUEZ, MIGUEL A. SEGUI-PALMER, BEATRIZ CIRAUQUI, MIREIA MARGELI, ARRATE PLAZAOLA, AGUSTI BARNADAS, MARIBEL CASAS, ROSALIA CABALLERO, EVA CARRASCO, FEDERICO ROJO

The Oncologist 2016;21:150–155; first published on January 19, 2016; <http://dx.doi:10.1634/theoncologist.2015-0312>

The online version of this article has been amended to correct errors that appear in Table 1 on page 152. A row was added to the “Treatment” section to provide missing MDH treatment data. In the “Histologic grade” section, the percentage noted for “GX” in the “pCR = no” column was incorrect; the correct percentage is 73.3. An errant comma in the “G3” heading was removed. For clarity, the heading of the last row of the table was changed to read “Ki67, median (range), %”.